Jiangsu Hengrui Pharmaceuticals (01276): HRS-8364 tablets receive clinical trial approval notification letter.
Hengrui Medicine (01276) announced that recently, the company received the approval and issuance of HRS-836 by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (01276) announced that the company recently received the approval notice from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, and will soon commence the clinical trial.
HRS-8364 is an innovative anti-tumor drug independently developed by the company, intended for the treatment of late-stage solid tumors. Upon inquiry, there is currently no similar approved drug on the market both domestically and internationally. As of now, the total research and development expenditure for the HRS-8364 tablet project is approximately 21.65 million yuan.
Related Articles
GUOFUHEE (02582) plans to sell a maximum of 4.8584 million shares at a discount of approximately 10%, raising about HK$197 million.
ALCO HOLD-OLD (00328): Executive Director and Authorized Representative He Zeyu passed away.
Miracle Automation Engineering (002009.SZ) plans to sell 7% equity of UQI Intelligent for a price of 130 million yuan.
GUOFUHEE (02582) plans to sell a maximum of 4.8584 million shares at a discount of approximately 10%, raising about HK$197 million.
ALCO HOLD-OLD (00328): Executive Director and Authorized Representative He Zeyu passed away.
Miracle Automation Engineering (002009.SZ) plans to sell 7% equity of UQI Intelligent for a price of 130 million yuan.
RECOMMEND
Foreign Brands “Take On Chinese Names”: Starbucks And Burger King Change Hands As Chinese Capital’s Localization Scalpel Rewrites Global Rules
25/11/2025
Riding The Momentum Of Gemini 3, “Google Chain” Challenges “Nvidia Chain,” Reshaping The Ai Trading Landscape
25/11/2025
Silver Economy Accelerates As Personal Pension System Marks Three Years — Structural Changes Emerging
25/11/2025
